The structural and spatial heterogeneity of the tumor microenvironment in human epidermal growth factor receptor 2-positive (HER2+) breast cancer (HER2+BC) poses major challenges for predicting pathologic complete response (pCR) to neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.